Table 1.
Clinical characterization of the entire epithelial ovarian cancer (EOC) dataset and the 117 patients receiving topotecan.
| Characteristics | All EOC Patients (%) | Topotecan-Treated EOC Patients (%) | ||
|---|---|---|---|---|
| Stage | ||||
| I | 6.7 | 0.9 | ||
| II | 4.7 | 2.6 | ||
| III | 64.0 | 84.6 | ||
| IV | 11.3 | 11.1 | ||
| N/A | 13.4 | 0.9 | ||
| Grade | ||||
| I | 2.6 | 16.2 | ||
| II | 17.8 | 80.3 | ||
| III | 58.3 | 0.9 | ||
| IV | 1.3 | 2.6 | ||
| N/A | 20.0 | |||
| Subtype | ||||
| Serous | 76.9 | 100 | ||
| Endometrioid | 3.6 | |||
| Clear | 2.2 | |||
| N/A | 17.4 | |||
| Debulking | ||||
| Optimal | 48.5 | 74.4 | ||
| Suboptimal | 32.0 | 22.2 | ||
| N/A | 19.5 | 3.4 | ||
| Progression | (median follow up 16.3 months) | 68.1 | (median follow up 14.8 months) | 88.0 |
| Treatment | ||||
| Platinum | 87.7 | 100 | ||
| Taxol | 49.8 | |||
| Combined platinum and taxol | 48.6 | 75.2 | ||
| Bevacizumab | 3.5 | 12.8 | ||
| Docetaxel | 7.4 | 30.8 | ||
| Gemcitabine | 9.1 | 62.4 | ||
| Paclitaxel | 15.9 | 25.6 | ||
| Topotecan | 8.2 | 100 |